Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

23. April 2019 08:00 ET | Quelle: VBI Vaccines, Inc.

VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call

10mcg dose selected to advance into Part B of Phase 1/2a study of VBI-1901 in recurrent GBMExpanded data from Part A of the Phase 1/2a study of VBI-1901 selected for poster presentation at...
03. April 2019 08:00 ET | Quelle: VBI Vaccines, Inc.

VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop

CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
25. Februar 2019 08:00 ET | Quelle: VBI Vaccines, Inc.

VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results

Top-line data from Hepatitis B (Sci-B-Vac®) Phase 3 PROTECT trial expected mid-year 2019Encouraging early immunogenicity data from GBM Phase 1/2a supports advancing into Part B of the studyLicense and...